Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Predictors of immunotherapy benefit in Merkel cell carcinoma
Alec J. Kacew
, Harita Dharaneeswaran
, Gabriel J. Starrett
, Manisha Thakuria
,
Nicole R. LeBoeuf
, Ann W. Silk
, James A. DeCaprio
, Glenn J. Hanna
Research output
:
Contribution to journal
›
Article
›
peer-review
13
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Predictors of immunotherapy benefit in Merkel cell carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Disease Diagnosis
100%
Disease-free Interval
100%
Merkel Cell Carcinoma
100%
Immunotherapy Benefit
100%
Odds Ratio
66%
Primary Disease
66%
ARID2
66%
95% Confidence Interval
66%
Recurrent/metastatic Disease
66%
Standard of Care
33%
Molecular Mechanism
33%
Median Overall Survival
33%
Advanced Stage
33%
Outcome Prediction
33%
Therapeutic Target
33%
Duration of Response
33%
Stage IV Disease
33%
Prognostic Biomarker
33%
Patient Benefit
33%
Molecular Findings
33%
Initial Treatment
33%
Objective Response
33%
Unmet Needs
33%
Electronic Health Records
33%
Predictive Marker
33%
Stage III Disease
33%
Single nucleotide Variant
33%
Bonferroni Correction
33%
Next-generation Sequencing Data
33%
Rare Cancer
33%
Mutational Signatures
33%
TRK Inhibitors
33%
Merkel Cell Polyomavirus (MCPyV)
33%
Tumor mutational Burden
33%
Immune Checkpoint Blockade
33%
Copy number Alterations
33%
Treatment Lines
33%
Medicine and Dentistry
Diseases
100%
Immunotherapy
100%
Merkel Cell Carcinoma
100%
Metastatic Carcinoma
40%
Odds Ratio
40%
Next Generation Sequencing
20%
Biological Marker
20%
Malignant Neoplasm
20%
Recurrent Disease
20%
Overall Survival
20%
Electronic Health Record
20%
Predictive Marker
20%
Single Nucleotide Polymorphism
20%
Merkel cell polyomavirus
20%
Immune Checkpoint Blockade
20%
Genetics
20%
Therapeutic Target
20%
Median Follow Up
20%
Immunology and Microbiology
Immunotherapy
100%
Merkel Cell
100%
Overall Survival
20%
Single Nucleotide Polymorphism
20%
Next Generation Sequencing
20%
Merkel cell polyomavirus
20%
Immune Checkpoint Blockade
20%
Electronic Health Record
20%
Therapeutic Target
20%
Neuroscience
Immunotherapy
100%
Merkel Cell
100%
Single-Nucleotide Polymorphism
20%
Merkel cell polyomavirus
20%
Genetics
20%
Biological Marker
20%